Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 3/20 | 0.44 |
| ▸ | RUNX1 | Q01196 | 2/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | CTSA | P10619 | 1/20 | 0.40 |
| ▸ | ABL1 | P00519 | 4/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | IGF1R | P08069 | 1/20 | 0.39 |
| ▸ | GPR3 | P46089 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14281982 | 0.85 | CRHR1 (0.43) | CRHR1RUNX1SCN9ACYP1A2CYP3A4 | |
| SCHEMBL4629107 | 0.79 | CYP1A2 (0.43) | CRHR1SCN9ACYP1A2CYP3A4TSHR | |
| SCHEMBL14281981 | 0.74 | ABL1 (0.44) | CRHR1RUNX1SCN9AABL1 | |
| SCHEMBL30451078 | 0.74 | CYP1A1 (0.55) | CRHR1CYP1A2CYP3A4TSHRCYP2C19 | |
| SCHEMBL26985646 | 0.73 | CYP1A2 (0.65) | CYP1A2CYP3A4TSHRCYP2C19ALOX15 | |
| SCHEMBL31506117 | 0.73 | CYP1A2 (0.65) | CYP1A2CYP3A4TSHRCYP2C19ALOX15 | |
| SCHEMBL6286387 | 0.72 | CRHR1 (0.61) | CRHR1RUNX1SCN9ACYP1A2CYP3A4 | |
| SCHEMBL12422184 | 0.70 | CA12 (0.61) | RUNX1CYP1A2CYP2C19GPR3 | |
| SCHEMBL15769209 | 0.70 | DYRK1A (0.47) | CYP1A2ABL1GPR3SCN5A | |
| SCHEMBL20460397 | 0.70 | RUNX1 (0.54) | RUNX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015196-A1 | Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands | NEUROGEN CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
| US-20080015196-A1 | Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands | NEUROGEN CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015196-A1 | Imidazopyrazines, Imidazopyridines, and Imidazopyrimidines as Crf1 Receptor Ligands | CRHR1, CRHR2, CRHBP | CRHR1 1/4885RUNX1 1849/4885SCN9A 4698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.